This site is intended for healthcare professionals
Drug News

Myovant Sciences submits NDA to the FDA for once-daily, oral relugolix for the treatment of men with advanced prostate cancer.

Read time: 1 mins
Last updated:28th Jun 2021
Published:22nd Apr 2020
Condition: Prostate Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest